Infectious Diseases

Our company is committed to discovering and developing innovative medicines and vaccines to treat and prevent infectious diseases.

Our commitments

We will invest in research and development to address infectious diseases that have a significant global public health burden, including in low- and middle-income countries, and where emerging science suggests opportunities to substantively reduce this burden through medicines or vaccines.

Our decades of research in infectious diseases have led to profound scientific advances, from developing one of the first antibiotics to pioneering HIV science.

For more than 100 years, our company has played a significant role in infectious diseases and we continue to collaborate with diverse stakeholders seeking an end to those diseases which threaten people and communities around the world.

Today, our company remains a global leader in infectious diseases. Our broad portfolio includes medicines for human immunodeficiency viruses (HIV), hepatitis C (HCV), neglected tropical diseases (NTDs), cytomegalovirus (CMV), bacterial infections, and fungal infections. Our pipeline is focused on addressing unmet needs in infectious diseases. Our work is far from done.

Infectious diseases are a leading cause of death worldwide, particularly in low- and middle-income countries. According to the World Health Organization (WHO), three of the top ten causes of death worldwide in 2016 were due to infectious diseases, accounting for approximately 5.7 million deaths worldwide. In low-income countries, five of the top ten causes of death were due to infectious diseases.

Our approach

We apply our research and development resources, expertise and technology to identifying potential products that would address unmet needs in the treatment of infectious diseases. We have multiple programs that span discovery through late-stage development. We are also involved in a number of product-development partnerships and research collaborations to further develop treatments to address infectious diseases, including NTDs, malaria, and tuberculosis (TB).

Beyond our in-house research and engagement with external partners to address infectious diseases, we continue to seek new ways in which we can contribute expertise and resources to these disease areas.

As a company, we have enormous experience in inventing antivirals and vaccines. We, and many other biopharmaceutical companies, are actively engaged in scientific efforts to help find solutions to the COVID-19 pandemic. This pandemic underscores the need for our company and our industry to continue to invest in research for the greatest health threats.

Our company has partnered with the Bill & Melinda Gates Foundation and a consortium of life-sciences companies to accelerate the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19.

Read more about our response to COVID-19.

We recognize that new methods and a broader scope of collaborating—with both public and private entities—are critical to supporting continued investment in innovation and to enhancing access. This is true for all diseases, but it is especially true for diseases prevalent in low- and middle-income countries, for which the relevant expertise spans academia, local public health authorities, industry and international agencies. We continue to expand our interactions with these groups to provide relevant expertise and resources.